The Fujifilm X T50 kit has quietly dropped to its lowest price in 30 days, right in the middle of Amazon’s massive Black Friday atmosphere. It is one of those cool and practical additions to the festival lineup, offering a compact…
Author: admin
-

Milkesa Mengesha and Brigid Kosgei seal Shanghai Marathon 2025 titles
Ethiopia swept the podium in the men’s elite race, with 2024 Berlin Marathon winner Milkesa Mengesha claiming victory in 2:06:25, narrowly ahead of compatriot Dawit Wolde (2:06:27) and Deresa Geleta (2:06:36).
The wheelchair events were both…
Continue Reading
-

Sanya Vats wins maiden PSA title at JSW Sunil Verma Memorial 2025 squash
Indian squash player Sanya Vats defeated compatriot Nirupama Dubey in the final to win the women’s title at the JSW Sunil Verma Memorial 2025 squash tournament, which concluded in Thane, Maharashtra, on Sunday.
Fifth seed Sanya Vats, a former…
Continue Reading
-
Taylor Swift Just Taught a Master Class in How to Be Likable. Anyone Can Do It – Inc.com
- Taylor Swift Just Taught a Master Class in How to Be Likable. Anyone Can Do It Inc.com
- How Taylor Swift secretly jetted 3,500 miles from US to film new music video in Croydon shopping centre The Sun
- Why Fans Think Taylor Swift Is Filming an…
Continue Reading
-

The Strategist locks in their Lusail picks
It’s time for the penultimate round of the 2025 season – and in Qatar, strategy is in the balance.
Pirelli’s mandatory 25-lap stint limit means every driver must make at least two pit stops, transforming Sunday’s race. With Carlos starting…
Continue Reading
-
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
– Utilizing Ascletis’ Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9–, 30–, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate (NHP) studies.
– ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), was approximately 57-fold of retatrutide’s drug exposure in head-to-head NHP studies.
– Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.
– ASC37 in vitro activity was approximately 5-, 4- and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.
– Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets is expected in the second quarter of 2026.
– The Company will host a conference call in Mandarin at 10:00 a.m. China Standard Time on December 1, 2025.
HONG KONG, Nov. 30, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that it has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets for the treatment of obesity in the second quarter of 2026.
ASC37 oral tablets is the Company’s first incretin drug candidate developed with its proprietary Peptide Oral Transport ENhancement Technology (POTENT).
ASC37, a GLP-1R, GIPR, and GCGR triple peptide agonist, was discovered and optimized in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). ASC37 in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.
Utilizing Ascletis’ POTENT technology, ASC37 oral tablets achieved average absolute oral bioavailability[2] of 4.2%, which was approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC [3] formulation, respectively, in head-to-head non-human primate (NHP) studies. Furthermore, after oral administration, ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), with the POTENT formulation was approximately 57-fold of retatrutide’s drug exposure with the oral SNAC formulation, in head-to-head NHP studies.
Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.
“Selection of ASC37, a promising oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development once again demonstrates our strong R&D capabilities and our commitment to address the unmet needs for the treatment of obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Leveraging our proprietary technology platforms, including AISBDD and POTENT, Ascletis has successfully established a highly competitive, differentiated and diverse pipeline portfolio which can potentially effectively address the various treatment needs of patients with obesity and other metabolic diseases.”
[1] GLP-1R: glucagon-like peptide 1 receptor, GIPR: gastric inhibitory polypeptide receptor, GCGR: glucagon receptor
[2] absolute oral bioavailability: the percentage of an orally administered drug that reaches the systemic circulation (bloodstream), compared to an intravenous (IV) dose of the same drug
[3] SNAC: Salcaprozate Sodium
Conference Call
Ascletis will host a conference call in Mandarin at 10:00 a.m. China Standard Time on December 1, 2025. A live webcast of the call will be available via Tencent Meeting/ VooV Meeting, with the Meeting ID: 495-266-842, or access links of:
Chinese Mainland: https://meeting.tencent.com/dm/10ve6whW8Rbl; or
International: https://voovmeeting.com/dm/10ve6whW8Rbl.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
For more information, please visit www.ascletis.com.
Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
[email protected]Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
[email protected]
[email protected]SOURCE Ascletis Pharma Inc.

Continue Reading
-

Doctor shares 6 superfoods that can improve blood sugar balance and insulin sensitivity: Chia seeds, apple cider vinegar
If you’re living with diabetes and looking to improve insulin sensitivity and stabilise your blood sugar, your everyday food choices can make a meaningful difference. Nutrition plays a central role in glucose management, and incorporating the…
Continue Reading
-

AC Milan take Serie A lead after fraught win over Lazio
AC Milan’s Rafael Leao celebrates scoring their first goal. Photo: REUTERS
MILAN:
…Continue Reading
-

Popping antacids every day? Apollo doctor warns your ‘normal acidity’ may be a slow-burning disease leading to much serious issues
A daily cycle of heartburn, gas, and throat irritation may seem routine for many Indians who rely on antacids as casually as after-meal mints. But according to a recent public advisory by Surgical Gastroenterology Specialist Dr Anshuman Kaushal…Continue Reading
-

AI-assisted shopping is the talk of the holiday shopping season
NEW YORK (AP) — Major retail chains and tech companies are offering new or updated artificial intelligence tools in time for the holiday shopping season, hoping to give consumers an easier gift-buying experience and themselves an augmented share of online spending.
Although AI-powered purchases are in early stages, the shopping assistants and agents rolled out by the likes of Walmart, Amazon and Google can do more than the chatbots of holidays past. The latest versions were designed to provide personalized product recommendations, track prices and to place some orders through unscripted “conversations” with customers.
Those features are on top of shopping updates from AI platforms like OpenAI’s ChatGPT and Google Gemini. In one of the season’s most talked-about launches, Google this month introduced an AI agent that can be instructed to call local stores to ask if a desired product is in stock.
San Francisco software company Salesforce estimated that AI would influence $73 billion, or 22%, of all global sales in one way or another from the Tuesday before Thanksgiving through Monday after the holiday, according to Caila Schwartz, Salesforce’s director of consumer insights.
The figure, which stood at $60 billion a year ago, encompasses everything from a ChatGPT query to AI-supplied gift suggestions on a retailer’s website, Schwartz said.
Despite the advancements, AI’s impact on holiday shopping will be “relatively limited” this year since not every shopping site has useful tools and not every shopper is willing to try them, said Brad Jashinsky, a senior retail industry analyst at information technology research and consulting firm Gartner.
“The more retailers that launch these tools, the better they get, and the more that consumers get comfortable and start to seek them out,” Jashinsky said. “But customer behavior takes a long time to change.”
Here are three ways the technology is poised to influence holiday shopping habits in 2025:
Bypassing the search bar
AI’s potential to simplify the search for the perfect present is most apparent so far in tools that promise to give shoppers faster and more detailed results than a web browser with a lot fewer clicks.
OpenAI upgraded ChatGPT with a shopping research feature that provides personalized buyers’ guides. The information comes from product pages, reviews. prices and a user’s previous interactions with the chatbot. The tool works best for complicated products like electronics and appliances, or for “detail-heavy” items like beauty or sporting goods, OpenAI said.
Continue Reading
